News

Osteogenesis Imperfecta (OI) is a rare, chronic genetic disorder that results in bones that can break easily. The Company intends to initiate a potential registration trial of BPS-804

ICOS is a co-stimulatory receptor that enhances T-cell responses and results in an increased anti-tumour response from the immune system.ICOS is a co-stimulatory receptor that enhances T-cell responses

The phase 2 study included 121 extremely premature infants born before 28 weeks’ gestation who were randomized to receive SHP607 or standard neonatal care and were treated until

Enadenotucirev has the capacity to selectively destroy tumour cells and alert cells of the immune system in the process. Opdivo is indicated to treat melanoma, lung cancer or

The collaboration will bring together Merck’s immuno-oncology know-how and Moderna’s mRNA vaccine technology and GMP manufacturing capabilities. Moderna’s mRNA vaccine technology will be used to develop personalized cancer

AbbVie company Pharmacyclics and Janssen Biotech are jointly developing and commercializing Imbruvica, which is oral, once-daily therapy that inhibits Bruton’s tyrosine kinase (BTK) protein. The breakthrough therapy designation

Roche’s marketing authorization application of the drug has been validated by the EMA to treat relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), confirming that the

Sanofi will transfer ownership of the €11.4bn Merial animal health business to Boehringer in return for the latter’s consumer healthcare (CHC) business, valued at €6.7bn and €4.7bn of

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for